RESUMEN
The dose-response relationship in the intravenous immunoglobulin treatment of idiopathic thrombocytopenic purpura was studied in 20 adult patients in a multicenter prospective crossover trial. The rate of response increases from 3 out of 11 (27%) to 6 out of 10 treatment periods (60%) by raising the 7S-IgG dose given on 5 consecutive days from 164.50 +/- 24.55 to 359.65 +/- 58.62 mg/kg body weight. The onset and duration of response as well as the peak platelet count were found to be independent of the doses. A long-term benefit induced by intravenous immunoglobulin treatment could be achieved in 2 out of 14 patients with chronic idiopathic thrombocytopenic purpura.
Asunto(s)
Inmunoglobulina G/uso terapéutico , Púrpura Trombocitopénica/terapia , Adolescente , Adulto , Anciano , Ensayos Clínicos como Asunto , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Infusiones Intravenosas , Masculino , Persona de Mediana Edad , Recuento de Plaquetas/efectos de los fármacosRESUMEN
A prospective randomized study comparing 7S immunoglobulin G to a 5S IgG preparation for therapy of acute idiopathic thrombocytopenic purpura was conducted. The 5S preparation differed from the 7S preparation in that it lacked part of the Fc portion of the IgG molecule. Both groups were given 400 mg IgG/kg body weight over 5 days. All patients had platelet counts less than or equal to 30 X 10(9)/L before IgG infusion. Nine of the 10 patients in the 7S treatment group, compared with three of 10 patients in the 5S treatment group, responded to therapy with an increment in platelet counts greater than 100 X 10(9)/L within 4 days of completing the infusion treatment. Furthermore, the rate of increase of the platelets was more rapid in the 7S group. The results emphasize the efficacy of partial Fc for management of acute idiopathic thrombocytopenic purpura.
Asunto(s)
Púrpura Trombocitopénica/terapia , gammaglobulinas/uso terapéutico , Enfermedad Aguda , Adolescente , Niño , Preescolar , Ensayos Clínicos como Asunto , Femenino , Humanos , Masculino , Recuento de Plaquetas , Estudios Prospectivos , Púrpura Trombocitopénica/sangre , Distribución AleatoriaRESUMEN
Chickenpox, which normally is an innocuous disease in children, may cause serious sequelae in immunocompromised hosts. An open prospective study is presented, that comprised 96 of such patients. They were treated with 0,2 ml/kg Varicella-Zoster-Immunoglobulin (VZIG) prophylactically or after exposure. The immunoglobulin was given in between 72 hours after known contact, newborns received the injection at the day of delivery. After that the patients were followed for six weeks for documentation and assessment of protection. In 85 (88,5%) cases there was no manifestation of varicella. 10 patients showed mild forms of the disease; 3 of these had got the preparation within the recommended time gap of 72 hours after exposure. One child died from varicella pneumonia and haemorrhage. In this case the preparation had only been given 10 days after contact.
Asunto(s)
Varicela/prevención & control , Inmunización Pasiva/métodos , Adolescente , Adulto , Anciano , Varicela/inmunología , Niño , Preescolar , Evaluación de Medicamentos , Femenino , Herpesvirus Humano 3/inmunología , Humanos , Sueros Inmunes/administración & dosificación , Sueros Inmunes/inmunología , Tolerancia Inmunológica , Lactante , Recién Nacido , Masculino , Persona de Mediana Edad , Embarazo , Estudios Prospectivos , RiesgoRESUMEN
Infectious diseases are the most serious complications in immunosuppressed patients and the major cause of death in renal transplant recipients (23, 44). Besides bacterial, fungal and protozoan infections, viruses of the human herpes group (herpes simplex virus, varicella-zoster virus, Epstein-Barr virus, cytomegalovirus) are known to be of major importance (21, 37). The most common and clinically relevant virus of this group is the cytomegalovirus (CMV).
Asunto(s)
Infecciones por Citomegalovirus/prevención & control , Citomegalovirus/inmunología , Inmunoglobulina G/uso terapéutico , Trasplante de Riñón , Adolescente , Adulto , Anciano , Anticuerpos Antivirales , Niño , Preescolar , Ensayos Clínicos como Asunto , Pruebas de Fijación del Complemento , Infecciones por Citomegalovirus/inmunología , Ensayo de Inmunoadsorción Enzimática , Femenino , Estudios de Seguimiento , Humanos , Inmunoglobulina G/administración & dosificación , Inyecciones Intramusculares , Masculino , Persona de Mediana Edad , Embarazo , Estudios ProspectivosRESUMEN
22 Rh-positive patients suffering from vitreous hemorrhage caused by injuries to the eye, hypertension, or associated with subarachnoid hemorrhage, were treated with anti-Rh-immunoglobulin by intravitreal injection. 8 patients (36.4%) needed only one immunoglobulin injection and rapidly regained their former visual acuity. In 2 cases with repeated hemorrhage the result of the treatment was not satisfactory. The incidence of adverse effects was low.
Asunto(s)
Hemorragia/terapia , Inmunización Pasiva , Sistema del Grupo Sanguíneo Rh-Hr/inmunología , Cuerpo Vítreo , Adulto , Oftalmopatías/terapia , Femenino , Humanos , Inmunoglobulinas/administración & dosificación , Inyecciones , Masculino , Globulina Inmune rho(D)Asunto(s)
Varicela/prevención & control , Herpes Zóster/prevención & control , Herpesvirus Humano 3/inmunología , Sueros Inmunes , Inmunización Pasiva , Adolescente , Niño , Preescolar , Método Doble Ciego , Femenino , Humanos , Síndromes de Inmunodeficiencia/complicaciones , Lactante , Recién Nacido , Masculino , RiesgoRESUMEN
Results are given on tolerability and bioavailability of an intramuscular immunoglobulin (Ig) preparation (BI 2.011) with high titer against cytomegalo-virus (CMV). For rapid and long-lasting protection a dosage of 0.2 ml/kg body weight anti-CMV-Ig with a titer of 1:50 000 (Enzyme-Linked Immunosorbent Assay) is recommended. Prophylaxis should be taken into account in seronegative patients suffering from immune defects, that experience transplantation surgery and/or multiple injections of blood products.
Asunto(s)
Anticuerpos Antivirales/administración & dosificación , Citomegalovirus/inmunología , Adulto , Disponibilidad Biológica , Ensayo de Inmunoadsorción Enzimática , Humanos , Inmunoglobulina G/análisis , Masculino , Persona de Mediana Edad , Factores de TiempoRESUMEN
Rubella and its complications during pregnancy must be taken seriously, as 12-15% of german females being able to deliver are encountered without protective immunity. Depending on gestational age rate of malformation goes up to 60%. To prevent embryopathy general vaccination of the population is considered to be most effective. Application of rubella-immunoglobulin to seronegative expectant mothers is an emergency measure. Necessary are high dosage and rapid injection after suspicion of ambient rubella. The need for high dosage and rapid injection is based on results of clinical investigations, that have been carried out during the recent years.